By using our site you accept the terms of our cookie policy

Securities Fraud Investigation Of Ocular Therapeutix, Inc.

July 10, 2017


Block & Leviton LLP Announces Securities Fraud Investigation Of Ocular Therapeutix, Inc. (OCUL) And Encourages Shareholders To Contact The Firm 

Block & Leviton LLP, a securities litigation firm representing investors nationwide, is investigating whether Ocular Therapeutix, Inc. ("Ocular" or the "Company") (NASDAQ: OCUL) and certain of its officers and directors violated federal securities laws.

On Jul 6, 2017, near the close of trading, the investor website Seeking Alpha published an article entitled "Ocular: A Poke In The Eye," reporting that Ocular is on "the brink of collapse" and that they may be "misleading investors" about ongoing manufacturing issues and the Company's communications with the FDA about those issues.

On this news, Ocular's stock has fallen more than 30% to close at $7.12 on July 7, 2017, causing tens of millions in losses to shareholders.

Block & Leviton LLP is a Boston-based law firm representing investors nationwide. The firm's lawyers have collectively been prosecuting securities cases on behalf of individual and institutional investors for over 50 years, and have recovered billions of dollars on their behalf. Block & Leviton's investigations into corporate wrongdoing were recently covered by the New York Times.

Contact Us

+44 (0) 203 725 6841